Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
47.86
-0.13 (-0.27%)
At close: Dec 5, 2025, 4:00 PM EST
47.98
+0.12 (0.25%)
After-hours: Dec 5, 2025, 7:59 PM EST
Novo Nordisk Revenue
Novo Nordisk had revenue of 74.98B DKK in the quarter ending September 30, 2025, with 5.14% growth. This brings the company's revenue in the last twelve months to 315.60B, up 16.64% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
315.60B DKK
Revenue Growth
+16.64%
P/S Ratio
4.32
Revenue / Employee
4,080,247 DKK
Employees
77,349
Market Cap
214.27B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Abbott Laboratories | 43.84B |
NVO News
- 1 day ago - This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - The Motley Fool
- 1 day ago - India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact - Reuters
- 2 days ago - Wegovy's prices are going down, but they are ‘wildly different' — and confusing - Market Watch
- 2 days ago - Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment - Reuters
- 3 days ago - Novo Nordisk gears up for December Ozempic launch in India, sources say - Reuters
- 3 days ago - Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock? - The Motley Fool
- 3 days ago - Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials - Reuters
- 3 days ago - Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart - Seeking Alpha